๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Head and Neck Squamous Cell Carcinoma
Clinical trial register · China

Head and Neck Squamous Cell Carcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 18 Guangzhou 14 Chengdu 12 Beijing 9 Wuhan 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University7 Sichuan Baili Pharmaceutical Co., Ltd.7 West China Hospital6 Fudan University4 Beijing Tongren Hospital3
Site location
Shanghai18 Guangzhou14 Chengdu12 Beijing9 Wuhan6
All 33 locations
Target enrolment
to

Head and Neck Squamous Cell Carcinoma trials in China

58 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma
NCT07827872Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma, Early-stage Oral Cancer
DrugsNab-paclitaxel·Carboplatin·Tislelizumab
caohaotian
Phase 3
300
Guangzhou
2026-10-01
Recruiting
Online Sharing for Head & Neck Cancer Support
NCT07766226Head and Neck Squamous Cell Carcinoma
West China Hospital
Not applicable
120
Chengdu
2026-08-28
Not yet open
MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07677475Head and Neck Squamous Cell Carcinoma
DrugTislelizumab
Dongguan People's Hospital
Phase 2
65
Dongguan
2026-08-10
Recruiting
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07381075Head and Neck Squamous Cell Carcinoma
DrugsPenpulimab·Becotatug Vedotin·Bevacizumab
West China Hospital
Phase 2
90
Chengdu
2026-07-20
Recruiting
Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
NCT07586124Head and Neck Squamous Cell Carcinoma
DrugsBecotatug Vedotin·Pucotenlimab
Lepu Biopharma Co., Ltd.
Phase 2
80
Beijing, Fuzhou, Guangzhou, Shantou, Nanning, Shijiazhuang, Wuhan, Changsha
2026-07-06
Recruiting
Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC
NCT07572864Head and Neck Squamous Cell Carcinoma
DrugEngineered Mitochondrial Vaccine
West China Hospital
Phase 2
9
Chengdu
2026-06-29
Recruiting
Clinical Study of CFH Protein Via Ice Microneedles for Radiation-Induced Skin Fibrosis
NCT07567235Radiation-Induced Skin Fibrosis, Head and Neck Squamous Cell Carcinoma
West China Hospital
Phase 1
9
Chengdu
2026-06-15
Active, closed
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer
NCT07791602Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC
DrugTislelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
180
Beijing, Harbin, Shenyang, Taiyuan, Tianjin
2026-06-12
Not yet open
Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC
NCT07554768Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma
DrugAdebrelimab
Chen Chunyan
Phase 2
36
Guangzhou
2026-05-01
Not yet open
Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study
NCT07589049Head and Neck Squamous Cell Carcinoma
DrugsBecotatug Vedotin·Pucotenlimab
Sun Yat-sen University
Phase 2
42
Foshan, Guangzhou, Qingyuan, Shantou, Shenzhen, Zhanjiang, Ganzhou
2026-05
Recruiting
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07601737Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer, Neoadjuvant Therapy
DrugsAlbumin-Bound Paclitaxel /nab-Paclitaxel·Nimotuzumab·Cisplatin·Carboplatin
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
182
Shanghai
2026-04-20
Recruiting
H101 Plus TACE for r/m HNSCC
NCT07398664Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE
DrugH101
West China Hospital
Phase 2
20
Chengdu
2026-03-02
Not yet open
Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07393477Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
Sir Run Run Shaw Hospital
Phase 2
30
Hangzhou
2026-02
Recruiting
First in Human Study of SIM0610 in Solid Tumors
NCT07348211Advanced Solid Tumours, Non-Small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
260
Chongqing, Harbin, Shenyang, Jinan, Shanghai
2026-01-19
Recruiting
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
NCT07254585Head and Neck Squamous Cell Carcinoma
DrugsEnlonstobart·SYS6010
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2
70
Shanghai
2025-12-18
Recruiting
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT07274852Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Solid Tumors
DrugLutetium [177Lu] BL-ARC001
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Chengdu
2025-12-10
Recruiting
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT07232524Head and Neck Squamous Cell Carcinoma, Solid Tumor
DrugBL-M24D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
16
Chengdu
2025-12-10
Recruiting
A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma
NCT07105592Head and Neck Squamous Cell Carcinoma
DrugsNimotuzumab·Adebrelimab
Fudan University
Phase 1/2
68
Shanghai
2025-05-13
Recruiting
PDO Based Drug Sensitive Test in R/M HNSCC
NCT06686342Head and Neck Squamous Cell Carcinoma, Patient Derived Organoid, Drug Sensitive Test in Vitro
Huashan Hospital
Observational
100
Shanghai
2025-03-26
Not yet open
Reconstruction of Cervical Lymphatic System During Head and Neck Squamous Cell Carcinoma Surgery
NCT06815705Head and Neck Squamous Cell Carcinoma, Lymphedema, Secondary, Neck Lymph Dissection, Vascularized Lymph Node Transplantation
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
23
Guangzhou
2025-03-20
Active, closed
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
NCT06727565Head and Neck Squamous Cell Carcinoma
DrugsDomvanalimab·Zimberelimab·Carboplatin·Paclitaxel
Gilead Sciences
Phase 2
39
Chengdu, Hangzhou, Nanning, Shanghai, Wuhan
2025-02-18
Not yet open
Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT06814067Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
DrugsPembrolizumab·Bevacizumab
Fudan University
Phase 2
80
Shanghai
2025-02-10
Not yet open
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
NCT06699498Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, PD-L1, Anlotinib
DrugsPaclitaxel ๏ผˆAlbumin Bound๏ผ‰·Anlotinib·Etoposide·Cisplatin
The First Affiliated Hospital with Nanjing Medical University
Phase 2
45
Nanjing
2024-12-03
Recruiting
Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC
NCT06725498Head and Neck Squamous Cell Carcinoma
DrugsAlbumin-Bound Paclitaxel·Cisplatin
Beijing Tongren Hospital
Phase 2
50
Beijing
2024-12-01
Active, closed
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06668961Head and Neck Squamous Cell Carcinoma
DrugsSI-B001·SI-B003
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
48
Shanghai
2024-11-07
Recruiting
A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
NCT06601335Head and Neck Squamous Cell Carcinoma
DrugsAK117·Bevacizumab
Akeso
Phase 3
510
Wuhan, Chengdu
2024-10-30
Recruiting
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
NCT06194656Head and Neck Squamous Cell Carcinoma
Shanghai Institute Of Biological Products
Phase 2
81
Shanghai
2024-09-27
Recruiting
Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma
NCT06575322Head and Neck Squamous Cell Carcinoma
DrugCarboplatin (neoadjuvant๏ผ‰
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
302
Guanzhou
2024-09-01
Recruiting
The Value of CEUS in Assessing the Response of Cervical Lymph Nodes After NACI for HNSCC
NCT06727162Head and Neck Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
100
Guangzhou
2024-08-13
Active, closed
AK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT06508606Head and Neck Squamous Cell Carcinoma
DrugsAK117·Cadonilimab·Pemetrexed
West China Hospital
Phase 2
20
Chengdu
2024-08-01
Recruiting
AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
NCT06494995Head and Neck Squamous Cell Carcinoma
DrugsCadonilimab·Capecitabine
Fudan University
Phase 2
52
Shanghai
2024-07-03
Recruiting
A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT06444009Head and Neck Squamous Cell Carcinoma
DrugsPenpulimab·Cadonilimab·Bevacizumab
Lei Liu
Phase 2
90
Chengdu
2024-07-01
Recruiting
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
NCT06494943Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
DrugsCis-platinum·Paclitaxel·Tislelizumab
Fudan University
Phase 1/2
27
Shanghai
2024-06-26
Active, closed
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT06378177Head and Neck Squamous Cell Carcinoma
DrugsPaclitaxel·Tislelizumab
Lyvgen Biopharma Holdings Limited
Phase 2
64
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha
2024-06-21
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06437522Head and Neck Squamous Cell Carcinoma
DrugIza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
46
Shanghai
2024-06-07
By invitation
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
NCT06690216Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer
Man Hu
Phase 1/2
100
Jinan
2024-03-30
Recruiting
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma
NCT06323369Head and Neck Squamous Cell Carcinoma
DrugsCarboplatin (adjuvant๏ผ‰·Cisplatin ๏ผˆneoadjuvant๏ผ‰·Cisplatin๏ผˆadjuvant๏ผ‰·Nab-paclitaxel ๏ผˆneoadjuvant๏ผ‰
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
154
Guangzhou
2024-03-25
Recruiting
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06007729Head and Neck Squamous Cell Carcinoma
DrugHS-20093
Hansoh BioMedical R&D Company
Phase 2
170
Hefei, Beijing, Fuzhou, Guangzhou, Zhuhai, Nanning, Harbin, Zhengzhou
2023-12-18
Recruiting
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
NCT06170710Head and Neck Squamous Cell Carcinoma
DrugTislelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
173
Beijing
2023-12-01
Recruiting
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
NCT05952947Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis
DrugsFludarabine·Cyclophosphamide
HRYZ Biotech Co.
Phase 1
32
Shanghai
2023-11-01
Recruiting
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
NCT06081673Head and Neck Squamous Cell Carcinoma
DrugsPenpulimab·Albumin paclitaxel·Cisplatin
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
72
Shanghai
2023-10-30
Recruiting
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06006169Head and Neck Squamous Cell Carcinoma
DrugsSI-B003·Iza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
186
Shanghai
2023-10-20
Not yet open
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
NCT05993858Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
DrugPemetrexed
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
33
Wuhan
2023-10-20
Recruiting
Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC
NCT06100497Head and Neck Squamous Cell Carcinoma
DrugsPaclitaxel-albumin·Cisplatin·Pembrolizumab
Beijing Tongren Hospital
Phase 2
100
Beijing
2023-10-01
Not yet open
Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck
NCT06016413Head and Neck Squamous Cell Carcinoma
DrugsNab-paclitaxel·Carboplatin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
30
Guangzhou
2023-09-01
Recruiting
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
NCT06102395Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab
DrugsLiposomal paclitaxel·Nedaplatin·Nab-paclitaxel·Cisplatin
Beijing Tongren Hospital
Phase 3
272
Beijing
2023-05-01
Recruiting
The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With pCR/MPR
NCT05854823Head and Neck Squamous Cell Carcinoma
Fifth Affiliated Hospital, Sun Yat-Sen University
Not applicable
23
Zhuhai
2023-04-10
Recruiting
Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC
NCT05941338Head and Neck Squamous Cell Carcinoma, Oral Cancer
DrugsTirelizumab·Albumin-Bound Paclitaxel·Carboplatin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
100
Guangzhou
2023-03-01
Active, closed
Toripalimab-based Neoadjuvant Therapy in LA-HNSCC
NCT05522985Head and Neck Squamous Cell Carcinoma, Neoadjuvant Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
122
Tianjin
2022-09-02
Recruiting
Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC
NCT05446467Head and Neck Squamous Cell Carcinoma
Zhejiang Provincial People's Hospital
Phase 2
80
Qingdao, Hangzhou, Ningbo, Tianjin, Wenzhou
2022-09-01
Active, closed
The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC
NCT05343325Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment
DrugTislelizumab
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 2
25
Zhuhai, Dongguan
2022-03-09
Recruiting
Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC
NCT05272696Head and Neck Squamous Cell Carcinoma
Guangdong Provincial People's Hospital
Phase 2
86
Guangzhou
2022-03-01
Active, closed
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC
NCT05054439Head and Neck Squamous Cell Carcinoma
DrugsSI-B001·Paclitaxel
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
45
Guilin, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2021-12-22
Active, closed
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
NCT05044897Head and Neck Squamous Cell Carcinoma
DrugSI-B001
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
11
Guilin, Guiyang, Shanghai
2021-10-20
Recruiting
Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)
NCT05044117Head and Neck Squamous Cell Carcinoma
DrugCapecitabine
Sun Yat-sen University
Phase 3
220
Guangzhou
2021-10-18
Recruiting
Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)
NCT04807140Head and Neck Squamous Cell Carcinoma
DrugTislelizumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
57
Guangzhou
2021-07-08
Active, closed
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT04843098Head and Neck Squamous Cell Carcinoma
DrugPaclitaxel
Suzhou Junde Biotechnology Co., Ltd
Phase 1/2
108
Shanghai
2021-05-26
Recruiting
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
NCT04857164Head and Neck Squamous Cell Carcinoma
DrugPembrolizumab
Yuankai Shi
Phase 2
150
Beijing
2021-04-30
Rows per page Showing 1–58 of 58
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/head-and-neck-squamous-cell-carcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 58 of those studies listing the condition Head and Neck Squamous Cell Carcinoma.

How many Head and Neck Squamous Cell Carcinoma trials are recruiting in China?

37 of the 58 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 10 have not yet opened recruitment, 10 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Head and Neck Squamous Cell Carcinoma), 58 studies
PhaseStudiesRecruitingShare
Phase 2392267.2%
Phase 1558.6%
Phase 1/2426.9%
Phase 3436.9%
Not applicable325.2%
Observational335.2%

Most active sponsors

Lead sponsors with the most studies (Head and Neck Squamous Cell Carcinoma)
Lead sponsorStudiesRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.74
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University75
West China Hospital65
Fudan University43
Beijing Tongren Hospital33
Cancer Institute and Hospital, Chinese Academy of Medical Sciences21
Fifth Affiliated Hospital, Sun Yat-Sen University21
Sun Yat-sen University21
Akeso11
caohaotian10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.